Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • drisapersen

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

    Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

    Uniphar

    - PMLiVE

    FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU

    Phenylketonuria affects one in every 13,500 to 19,000 newborns in the US

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

    Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

    - PMLiVE

    AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

    Around one in three patients with early-stage breast cancer are considered high risk

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

    Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

    More than 300,000 cases of breast cancer are diagnosed in the US every year

    - PMLiVE

    Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy

    The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

    - PMLiVE

    AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe

    The questionnaire gathered insights from 7,750 adults across five countries

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

    More than 300,000 cases of breast cancer are diagnosed in the US every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links